DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,839,009 | +37.3% | 7,412 | +32.9% | 0.04% | +33.3% |
| Q2 2023 | $1,339,005 | +0.0% | 5,579 | +5.0% | 0.03% | -16.7% |
| Q1 2023 | $1,338,809 | -16.6% | 5,311 | -12.2% | 0.04% | -12.2% |
| Q4 2022 | $1,606,022 | -2.8% | 6,050 | -5.4% | 0.04% | -10.9% |
| Q3 2022 | $1,653,000 | +5.2% | 6,398 | +3.2% | 0.05% | +15.0% |
| Q2 2022 | $1,572,000 | -8.4% | 6,199 | +6.0% | 0.04% | +5.3% |
| Q1 2022 | $1,716,000 | +8.1% | 5,848 | +21.2% | 0.04% | +8.6% |
| Q4 2021 | $1,587,000 | +8.3% | 4,824 | +0.3% | 0.04% | -5.4% |
| Q3 2021 | $1,465,000 | +20.2% | 4,811 | +5.9% | 0.04% | +23.3% |
| Q2 2021 | $1,219,000 | +30.8% | 4,542 | +9.7% | 0.03% | +15.4% |
| Q1 2021 | $932,000 | +32.4% | 4,140 | +30.6% | 0.03% | +23.8% |
| Q4 2020 | $704,000 | +1.4% | 3,169 | -1.6% | 0.02% | -8.7% |
| Q3 2020 | $694,000 | +22.6% | 3,221 | +0.6% | 0.02% | +15.0% |
| Q2 2020 | $566,000 | +28.3% | 3,203 | +0.6% | 0.02% | 0.0% |
| Q1 2020 | $441,000 | -9.6% | 3,185 | +0.2% | 0.02% | +5.3% |
| Q4 2019 | $488,000 | +10.7% | 3,179 | +4.2% | 0.02% | 0.0% |
| Q3 2019 | $441,000 | -6.0% | 3,052 | -7.0% | 0.02% | -5.0% |
| Q2 2019 | $469,000 | +12.2% | 3,281 | +3.5% | 0.02% | +5.3% |
| Q1 2019 | $418,000 | +28.2% | 3,170 | +0.3% | 0.02% | +11.8% |
| Q4 2018 | $326,000 | -3.8% | 3,160 | +1.3% | 0.02% | +13.3% |
| Q3 2018 | $339,000 | -5.3% | 3,120 | -13.9% | 0.02% | -6.2% |
| Q2 2018 | $358,000 | -5.5% | 3,625 | -6.4% | 0.02% | 0.0% |
| Q1 2018 | $379,000 | +3.3% | 3,871 | -2.2% | 0.02% | 0.0% |
| Q4 2017 | $367,000 | +6.4% | 3,957 | -1.6% | 0.02% | 0.0% |
| Q3 2017 | $345,000 | -2.8% | 4,021 | -4.5% | 0.02% | -11.1% |
| Q2 2017 | $355,000 | +2.0% | 4,209 | +3.6% | 0.02% | -10.0% |
| Q1 2017 | $348,000 | +16.4% | 4,063 | +5.6% | 0.02% | +5.3% |
| Q4 2016 | $299,000 | +23.0% | 3,846 | +23.9% | 0.02% | +18.8% |
| Q3 2016 | $243,000 | -4.0% | 3,104 | +23.7% | 0.02% | -15.8% |
| Q2 2016 | $253,000 | +20.5% | 2,510 | +13.6% | 0.02% | +5.6% |
| Q1 2016 | $210,000 | +2.9% | 2,210 | +0.6% | 0.02% | +5.9% |
| Q4 2015 | $204,000 | -12.4% | 2,196 | -19.5% | 0.02% | -41.4% |
| Q3 2015 | $233,000 | -7.5% | 2,727 | -7.3% | 0.03% | -9.4% |
| Q2 2015 | $252,000 | -7.4% | 2,942 | -8.5% | 0.03% | 0.0% |
| Q1 2015 | $272,000 | +9.7% | 3,217 | +11.2% | 0.03% | -28.9% |
| Q4 2014 | $248,000 | – | 2,893 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |